TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation
Open Access
- 7 January 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (2) , 395-410
Abstract
Background and Aims: Intrahepatic cholangiocarcinoma (ICC) is a deadly but poorly understood disease, and its treatment options are very limited. The aim of this study was to identify the molecular drivers of ICC and search for therapeutic targets. Approach and Results: We performed a Sleeping Beauty transposon‐based in vivo insertional mutagenesis screen in liver‐specific Pten‐deficient mice and identified TNF receptor–related factor 3 (Traf3) as the most significantly mutated gene in murine ICCs in a loss‐of‐function manner. Liver‐specific Traf3 deletion caused marked cholangiocyte overgrowth and spontaneous development of ICC in Pten knockout and Kras G12D mutant mice. Hepatocyte‐specific, but not cholangiocyte‐specific, Traf3‐deficient and Pten‐deficient mice recapitulated these phenotypes. Lineage tracing and single‐cell RNA sequencing suggested that these ICCs were derived from hepatocytes through transdifferentiation. TRAF3 and PTEN inhibition induced a transdifferentiation‐like phenotype of hepatocyte‐lineage cells into proliferative cholangiocytes through NF‐κB‐inducing kinase (NIK) up‐regulation in vitro. Intrahepatic NIK levels were elevated in liver‐specific Traf3‐deficient and Pten‐deficient mice, and NIK inhibition alleviated cholangiocyte overgrowth. In human ICCs, we identified an inverse correlation between TRAF3 and NIK expression, with low TRAF3 or high NIK expression associated with poor prognosis. Finally, we showed that NIK inhibition by a small molecule inhibitor or gene silencing suppressed the growth of multiple human ICC cells in vitro and ICC xenografts in vivo. Conclusions: TRAF3 inactivation promotes ICC development through NIK‐mediated hepatocyte transdifferentiation. The oncogenic TRAF3–NIK axis may be a potential therapeutic target for ICC.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP21fk0210074, JP21fk0210091s, JP21fk021055h, JP21fk0310108h0005)
This publication has 45 references indexed in Scilit:
- Tumor necrosis factor‐α promotes bile ductular transdifferentiation of mature rat hepatocytes in vitroJournal of Cellular Biochemistry, 2012
- Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytesJournal of Clinical Investigation, 2012
- Cholangiocarcinomas can originate from hepatocytes in miceJournal of Clinical Investigation, 2012
- Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in miceLeukemia, 2011
- Expanding TRAF function: TRAF3 as a tri-faced immune regulatorNature Reviews Immunology, 2011
- A CK19CreERT knockin mouse line allows for conditional DNA recombination in epithelial cells in multiple endodermal organsGenesis, 2008
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple MyelomaCancer Cell, 2007
- Rescue of TRAF3-null mice by p100 NF-κB deficiencyJournal of Experimental Medicine, 2006
- Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption ofSmad4 andPten in miceJournal of Clinical Investigation, 2006
- Dual Roles for Glucokinase in Glucose Homeostasis as Determined by Liver and Pancreatic β Cell-specific Gene Knock-outs Using Cre RecombinaseJournal of Biological Chemistry, 1999